Tech Company Financing Transactions

Silverback Therapeutics Funding Round

On 3/12/2020, Silverback Therapeutics raised $78.5 million in Series B investment from U.S. Venture Partners, Alexandria Venture Investments and Bristol-Myers Squibb.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

500 Fairview Ave. N 600
Seattle, WA 98109
USA

Phone

(206) 456-2900

Website

www.silverbacktx.com

Email Address

[email protected]

Overview

Silverback Therapeutics (Nasdaq: SBTX) is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness -- until now.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Laura Shawver

        

Chief Medical Officer

Naomi Hunder

        

Chief Scientific Officer

Valerie Odegard

        

Founder

Peter Thompson

        

Vice President

Sateesh Natarajan

        

VP - Finance

Russ Hawkinson

        

VP - General Counsel

Jeffrey Pepe

        

VP - Operations

Patricia Leith

        

Browse more venture capital transactions:

Prev: 3/12/2020: Wanted venture capital transaction
Next: 3/12/2020: Zeto venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary